MYASTHENIA GRAVIS (MG)
Clinical trials for MYASTHENIA GRAVIS (MG) explained in plain language.
Never miss a new study
Get alerted when new MYASTHENIA GRAVIS (MG) trials appear
Sign up with your email to follow new studies for MYASTHENIA GRAVIS (MG), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take on multiple sclerosis and other autoimmune brain diseases
Disease control Recruiting nowThis early-phase study tests a new treatment called RD06-05, which uses specially engineered immune cells (CAR-T cells) to target and calm the immune system in people with neurological autoimmune diseases like multiple sclerosis, myasthenia gravis, chronic inflammatory demyelinat…
Matched conditions: MYASTHENIA GRAVIS (MG)
Phase: EARLY_PHASE1 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Experimental cell therapy takes aim at Hard-to-Treat autoimmune diseases
Disease control Recruiting nowThis early-phase trial is testing a new cell therapy called QH103 for people with severe autoimmune diseases like multiple sclerosis and myasthenia gravis that haven't responded to standard treatments. The therapy uses specially engineered immune cells to target and attack the fa…
Matched conditions: MYASTHENIA GRAVIS (MG)
Phase: PHASE1 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
CAR t therapy takes on lupus, MS, and more in first human safety trial
Disease control Recruiting nowThis early-stage study tests a new treatment called HBI0101 CAR T for people with severe autoimmune diseases like lupus, multiple sclerosis, and rheumatoid arthritis that haven't improved with standard treatments. The main goal is to find a safe dose and check for side effects in…
Matched conditions: MYASTHENIA GRAVIS (MG)
Phase: PHASE1 • Sponsor: Polina Stepensky • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Experimental CAR-T shot targets three tough autoimmune diseases
Disease control Recruiting nowThis early study is testing an experimental therapy called EVM18001 in 12 people with active, hard-to-treat lupus, myasthenia gravis, or scleroderma. The main goal is to see if it is safe and to find the right dose. Researchers will also look at how the body processes the therapy…
Matched conditions: MYASTHENIA GRAVIS (MG)
Phase: NA • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC